Considerable time and effort has been spent in developing targeted therapies to fight SLE, yet only one therapy, belimumab (Benlysta), a monoclonal antibody targeting B cell-activating factor, or BAFF, has been approved for the treatment of SLE in the last half-century16. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.